中国银河证券股份有限公司 关于天津瑞普生物技术股份有限公司 使用闲置募集资金进行现金管理的核查意见 天津瑞普生物技术股份有限公司（以下简称"公司"）于2024年8月22日召开了第 五届董事会第十六次会议及第五届监事会第十三次会议，审议通过了《关于使用闲 置募集资金进行现金管理的议案》，同意公司及下属子公司在确保不影响募集资金 投资项目建设、不影响正常生产经营及确保资金安全的情况下，使用额度不超过5.5 亿元的闲置募集资金进行现金管理，在上述额度及期限内，资金可以滚动使用。上 述额度自董事会审议通过之日起12个月内有效，单笔理财产品期限最长不超过12个 月。根据《深圳证券交易所创业板股票上市规则（2024年修订）》第7.1.2和7.1.3条， 及《公司章程》第41和110条等相关规定，该事项在公司董事会审批权限范围内，无 需提交公司股东大会审议。 中国银河证券股份有限公司（以下简称"银河证券"或"保荐机构"）作为瑞普生 物2021年度向特定对象发行股票的保荐机构，对公司使用闲置募集资金进行现金管 理事项进行了核查，具体情况如下： 一、本次募集资金有关情况 经中国证券监督管理委员会《关于同意天津瑞普生物技术股份有 ...

Company Commitment and Strategy - The company reported a commitment to animal and human health, emphasizing harmony between people and nature[1]. - The company is focused on the development of veterinary biological products and veterinary drugs[5]. - The company is actively developing new products in the pet health market, including rabies vaccines and mRNA vaccines for cats, which are expected to drive continuous revenue growth[39]. - The company emphasizes a customer-centric approach in its internal organizational transformation to improve operational efficiency[38]. - The company aims to enhance its product competitiveness through continuous process improvements and high-quality product development[39]. - The company is focusing on product innovation, with a diverse product matrix that includes vaccines and functional additives for pigs, chickens, and pets[39]. - The company has established strategic partnerships with large livestock breeding groups and expanded its marketing network, leading to a high growth period in the livestock sector[39]. - The company has established a comprehensive technical service system for disease prevention and control, enhancing service capabilities in various areas including disease diagnosis and food safety[52]. Financial Performance - The company's operating revenue for the reporting period was ¥1,099,038,124.02, representing a year-on-year increase of 10.56% compared to ¥994,096,256.27 in the same period last year[12]. - The net profit attributable to shareholders was ¥159,139,372.47, a decrease of 10.73% from ¥178,271,133.74 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥138,304,200.94, down 9.31% from ¥152,502,477.59 year-on-year[12]. - The net cash flow from operating activities increased by 43.20% to ¥195,838,863.29 from ¥136,759,279.75 in the same period last year[12]. - Total assets at the end of the reporting period were ¥7,195,836,913.70, reflecting a 9.09% increase from ¥6,595,941,501.08 at the end of the previous year[12]. - The company's weighted average return on equity decreased to 3.51% from 4.13% in the previous year, a decline of 0.62%[12]. - The company reported a total of ¥20,835,171.53 in non-recurring gains and losses for the reporting period, primarily from government subsidies and investment income[14]. Market Trends and Risks - The veterinary medicine industry in China had a total sales revenue of ¥67.345 billion in 2022, with a compound annual growth rate of 5.91% over the past decade[17]. - The market for pet veterinary products in China is expected to grow significantly, as it accounted for less than 10% of the total veterinary sales in 2022, compared to 44% globally[19]. - The company faces risks including animal epidemic risks, market competition risks, and product development risks[2]. - The overall livestock production in the first half of 2024 was stable, with a total output of 47.12 million tons, reflecting a year-on-year growth of 0.6%[21]. - As of the end of Q2 2024, the total pig inventory in China was 41.53 million heads, a year-on-year decrease of 4.6%[22]. - The number of breeding sows decreased by 6.0% year-on-year to 4.04 million heads, indicating a tightening supply in the pork market[22]. Research and Development - The company invested CNY 232.83 million in R&D in 2023, accounting for 10.35% of revenue, and CNY 96.71 million in the first half of 2024, accounting for 8.80% of revenue[38]. - The company has achieved significant growth in group customer revenue, reflecting the increasing concentration and professionalization of the livestock industry[37]. - The company has developed a unique enteric-coated formulation for treating bacterial infections in pigs, with a bioavailability 1.41 times higher than conventional premixes[43]. - The company has developed several key technology platforms for gene engineering, enabling efficient expression of immunogenic proteins and the development of high-end vaccines[56]. - The company has established a robust emergency response plan for environmental incidents, ensuring preparedness and compliance with regulatory requirements[107]. Environmental Compliance - The company is subject to various environmental protection laws and standards, ensuring compliance in its operations[101]. - The company has established a comprehensive wastewater treatment station at the Tianjin Airport branch, utilizing a treatment process that includes pre-treatment, anaerobic, and oxidation processes, with normal equipment operation[106]. - The company has reported a total nitrogen oxide emission of 25mg/m³ from the Shanxi Ruixiang facility, adhering to local environmental standards[107]. - The company has implemented an environmental self-monitoring plan across all subsidiaries, with regular monitoring of wastewater and air emissions by qualified third-party agencies[107]. - The overall compliance with air and water pollutant standards reflects the company's commitment to environmental sustainability[103]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares for the first half of 2024[98]. - The company held its 2023 annual general meeting on April 19, 2024, with a participation rate of 46.25%[97]. - The company has not experienced any changes in its board of directors or senior management during the reporting period[97]. - The company’s major shareholders have committed to not reducing their holdings for a period of 6 months, reflecting confidence in the company's future[113]. - The company has maintained a commitment to avoid any conflicts of interest with its major shareholders[112]. Acquisitions and Investments - The company successfully acquired 100% equity of Baoding Shoujun, indirectly holding 55.20% of the equity of Biwei Antai, expanding its business into foot-and-mouth disease vaccines[70]. - The company completed the acquisition of 100% equity in Baoding Shoujun Technology Co., Ltd. for a total consideration of RMB 230 million, including RMB 4.6 million for a 2% stake held by an affiliate[122]. - The company has engaged with multiple institutional investors regarding its 2023 performance and 2024 product development plans[95]. - The company is actively pursuing mergers and acquisitions as part of its future growth strategy[95]. Financial Position and Liabilities - The total liabilities rose to CNY 2,312,863,264.08 from CNY 1,791,055,573.41, an increase of around 29.1%[154]. - The company’s total financial liabilities remained at 0.00 yuan at the end of the reporting period[81]. - The company reported a total investment commitment of 133.6 million yuan, with 39.66 million yuan allocated for working capital and repayment of bank loans[84]. - The company has no outstanding guarantees as of the reporting period, with a total approved external guarantee limit of RMB 20 million[128]. Community Engagement and Social Responsibility - The company donated CNY 254,500 to support rural revitalization and development in targeted assistance areas[110]. - The company has established veterinary service stations and hospitals in 5 leagues and 13 banners in Inner Mongolia to enhance disease prevention efforts[110]. - The company has established a public welfare foundation to support stray animals, providing medical care for nearly 1,000 stray dogs and cats[109]. - The company continues to focus on technological innovation and socialized veterinary services to create new employment opportunities[110].

证券代码:300119 证券简称:瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 编号:2024-005 □ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 投资者关系活动 □ 新闻发布会 □ 路演活动 类别 √ 现场参观 □ 其他 活动名称 "踔厉奋发新征程 投教服务再出发"主题投教活动——走进上 市公司瑞普生物 参与单位名称 深圳证券交易所、天津证监局、天津上市公司协会、天津市证券 业协会、渤海证券、华泰证券、银河证券及投资者 时间 2024 年 7 月 18 日 (周四) 9:30-11:00 地点 天津市空港经济区东九道 1 号公司会议室 董事、总裁 徐雷 上市公司接待人 董事会秘书 谢刚 员姓名 证券事务代表 赵文宇 一、参观公司展厅 二、参观公司研究院 三、公司经营情况介绍 瑞普生物集生物制品、药物制剂、药物原料、饲料添加剂 四大业务板块于一体,是中国兽药领域的领军企业,位居全球 投资者关系活动 兽药市场第 15 位。作为 A 股上市公司的一员,公司始终坚持创 主要内容介绍 新驱动高质量发展的战略方向,不断提升公司经营发展质量、 投资价值和可持续发展水平,积极回报投资者,维 ...

Investment Rating - The report maintains a "Buy" rating for the company [6]. Core Insights - The company has successfully launched its self-developed "Rui Miao Shu" cat trivalent vaccine, breaking the long-standing reliance on imported vaccines in the companion animal vaccine market. The vaccine has achieved significant sales and market penetration since its launch [12]. - The company is expected to achieve a net profit attributable to shareholders of 5.19 billion, 6.11 billion, and 7.40 billion yuan for the years 2024 to 2026, representing year-on-year growth rates of 14.6%, 17.7%, and 21.2%, respectively [5]. - The company is building a comprehensive pet industry ecosystem and aims to establish itself as a new industry benchmark [4]. Financial Forecasts - Revenue is projected to grow from 2,249 million yuan in 2023 to 3,364 million yuan in 2026, with annual growth rates of 7.90%, 23.45%, 11.43%, and 8.75% for the respective years [7]. - The company's net profit is forecasted to increase from 511 million yuan in 2023 to 835 million yuan in 2026, with growth rates of 30.64%, 14.59%, 17.67%, and 21.21% [7]. - Earnings per share (EPS) are expected to rise from 0.97 yuan in 2023 to 1.59 yuan in 2026 [7]. Strategic Initiatives - The company is implementing a strategy to capture opportunities in the pet market, aiming to release product value and establish itself as the leading domestic brand. It has set up a subsidiary, Lan Rui Biological, to independently operate its pet business [13]. - The company plans to launch several new products in 2024, including a compound dichlorobenzene pyrethroid dip solution and an upgraded rabies inactivated vaccine, to continue driving growth in its pet business [13].

证券代码：300119 证券简称：瑞普生物 公告编号：2024-039 天津瑞普生物技术股份有限公司 关于回购注销部分限制性股票减少注册资本 公司债权人自本公告披露之日起 45 日内，有权要求公司清偿债务或者提供 相应的担保。债权人未在规定期限内行使上述权利的，不会因此影响其债权的有 效性，相关债务（义务）将由公司根据原债权文件的约定继续履行，本次回购注 1 销将按法定程序继续实施。 债权人可采用信函或传真的方式申报，具体方式如下： 1、申报时间：2024 年 6 月 27 日至 2024 年 8 月 11 日，每个工作日 9:00— 11:30、14:00—17:00（双休日及法定节假日除外）。 2、申报地点及申报材料送达地点：天津自贸试验区（空港经济区）东九道 1 号。 暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）于 2024 年 6 月 11 日 召开第五届董事会第十五次（临时）会议及第五届监事会第十二次（临时）会议， 审议通过了《关于回购注销 2022 年限制性股票激励计划部分限制 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京市康达律师事务所 关于天津瑞普生物技术股份有限公司 2024 年第一次临时股东大会的法律意见书 康达股会字【2024】第 2068 号 致：天津瑞普生物技术股份有限公司 北京市康达律师事务所（以下简称"本所"）接受天津瑞普生物技术股份 有限公司（以下简称"公司"）的委托，指派本所律师参加公司 2024 年第一次 临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2024-038 天津瑞普生物技术股份有限公司 2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、本次股东大会无变更、否决议案的情况； 2、本次股东大会以现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 天津瑞普生物技术股份有限公司（以下简称"公司"）2024年6月11日以董事会 公告方式向全体股东发出召开2024年第一次临时股东大会的通知。（公告编号：2024- 035）。 1、审议通过了《关于回购注销 2022 年限制性股票激励计划部分限制性股票的 议案》 关联股东李守军对该议案回避表决，回避表决的股份共计 167,474,479 股。 表决结果为：同意 42,986,662 股，占出席本次股东大会有效表决权股份总数的 99.9358％；反对 100 股，占出席本次股东大会有效表决权股份总数的 0.0002％；弃 权 27,500 股（其中，因未投票默认弃权 0 股），占出席本次股东大会有效表决权股 份总数的 0.0639％。 中小股东总 ...

| 第一章 总则 | 1 | | --- | --- | | 第二章 经营宗旨和范围 | 2 | | 第一节 | 股份发行 2 | | 第二节 | 股份增减和回购 3 | | 第三节 | 股份转让 5 | | 第三章 股东和股东大会 | 5 | | 第一节 | 股东 5 | | 第二节 | 股东大会的一般规定 8 | | 第三节 | 股东大会的召集 12 | | 第四节 | 股东大会的提案与通知 13 | | 第五节 | 股东大会的召开 15 | | 第六节 | 股东大会的表决和决议 18 | | 第四章 董事会 | 21 | | 第一节 | 董事 21 | | 第二节 | 董事会 24 | | 第三节 | 董事会专门委员会 30 | | 第五章 总经理及其他高级管理人员 | 31 | | 第六章 监事会 | 33 | | 第一节 | 监事 33 | | 第二节 | 监事会 33 | | 第七章 财务会计制度、利润分配和审计 | 35 | | 第一节 | 财务会计制度 35 | | 第二节 | 内部审计 38 | | 第三节 | 会计师事务所的聘任 39 | | 第八章 通知与公告 | 39 | | 第一节 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2024-037 天津瑞普生物技术股份有限公司 关于 2022 年限制性股票激励计划第二个解除限售期 解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1、本次符合解除限售条件的激励对象人数：174 人 2、解除限售股数：本次限制性股票解除限售数量为 829,920 股，占目前公 司总股本 466,276,186 股的 0.1780%； 3、本次解除限售的限制性股票的上市流通日为 2024 年 6 月 19 日。 天津瑞普生物技术股份有限公司（以下简称"公司"）于 2024 年 6 月 11 日 召开的第五届董事会第十五次（临时）会议及第五届监事会第十二次（临时）会 议审议通过了《关于 2022 年限制性股票激励计划第二个解除限售期解除限售条 件成就的议案》，公司 2022 年限制性股票激励计划所涉及的限制性股票第二个 解除限售期解除限售条件已成就，根据公司 2022 年第一次临时股东大会对董事 会的授权，公司办理了 2022 年限制性股票激励计划第二个解除限 ...

Investment Rating - The report assigns an "Outperform" rating to the company [7]. Core Insights - The company, Ruipubio, is a leading player in the livestock health sector, actively expanding into the pet health market. It has established itself as one of the largest and most comprehensive animal health enterprises in China since its inception in 1998 [7][24]. - In 2023, the company's revenue reached 2.249 billion yuan, with a CAGR of 11% over the past decade. The pet health segment is entering a growth phase, with several self-developed products, including a cat trivalent vaccine, expected to contribute to revenue growth [7][34]. - The company is well-positioned to benefit from the recovery of the livestock breeding industry, with expectations of improved demand for veterinary products as cash flow and profitability in the breeding sector recover [7][34]. Summary by Sections Company Overview - Ruipubio focuses on the research, production, and sales of veterinary biological products and pharmaceuticals, providing comprehensive solutions for animal disease prevention and control [7][24]. Financial Performance - In 2023, the company reported a revenue of 2.249 billion yuan, a year-on-year increase of 7.9%. The net profit attributable to shareholders was 453 million yuan, reflecting a 30.6% increase year-on-year [8][34]. - The company’s revenue and net profit have shown a CAGR of 11.53% and 11.54% respectively from 2013 to 2023 [34][37]. Business Segments - The revenue breakdown for 2023 shows that raw materials and formulations accounted for 48%, poultry biological products for 41%, and livestock biological products for 6% of total revenue [56]. - The pet health segment generated revenue of 26.52 million yuan in 2023, with expectations for growth as new products are launched [56]. Market Position - Ruipubio is recognized as one of the largest animal health companies in China, with a comprehensive product portfolio and a strong focus on R&D, leading to a competitive edge in the market [7][24][28]. Profitability and Valuation - The company’s gross margin for 2023 was 49.69%, with a net margin of 22.72%, indicating a stable profitability profile despite market challenges [40][34]. - The estimated reasonable valuation range for the company's stock is between 17.8 and 19.1 yuan, suggesting a potential upside of 20%-30% from the current stock price [7].